Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRDL Stock Forecast 2026-2027
$1.51
Current Price
$168.64M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CRDL Price Targets
+505.7%
To High Target of $9.15
+417.9%
To Median Target of $7.82
+229.4%
To Low Target of $4.97
CRDL Price Momentum
+7.9%
1 Week Change
+62.4%
1 Month Change
+55.7%
1 Year Change
+58.9%
Year-to-Date Change
-5.0%
From 52W High of $1.59
+71.6%
From 52W Low of $0.88
📊 TOP ANALYST CALLS
Did CRDL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cardiol is one of their latest high-conviction picks.
Latest CRDL Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, CRDL has a bullish consensus with a median price target of $7.82 (ranging from $4.97 to $9.15). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $1.51, the median forecast implies a 417.9% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRDL Analyst Ratings
5
Buy
0
Hold
0
Sell
CRDL Price Target Range
Low
$4.97
Average
$7.82
High
$9.15
Current: $1.51
Latest CRDL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRDL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 6, 2026 | Canaccord Genuity | Edward Nash | Buy | Maintains | $8.00 |
| Feb 10, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $9.00 |
| Dec 1, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $9.00 |
| Jun 2, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Initiates | $9.00 |
| Apr 16, 2025 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Apr 7, 2025 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Feb 24, 2025 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Dec 18, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Oct 24, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Jun 26, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $10.00 |
| Jun 14, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Jun 7, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| May 23, 2024 | Canaccord Genuity | Edward Nash | Buy | Maintains | $8.00 |
| May 14, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Reiterates | $9.00 |
| Apr 22, 2024 | HC Wainwright & Co. | Vernon Bernardino | Buy | Initiates | $9.00 |
| Aug 14, 2023 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $3.00 |
| May 19, 2023 | Canaccord Genuity | Edward Nash | Buy | Maintains | $6.00 |
| Dec 22, 2021 | Canaccord Genuity | Buy | Initiates | $N/A | |
| Dec 22, 2021 | Cantor Fitzgerald | Overweight | Initiates | $N/A |
Cardiol Therapeutics Inc. (CRDL) Competitors
The following stocks are similar to Cardiol based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cardiol Therapeutics Inc. (CRDL) Financial Data
Cardiol Therapeutics Inc. has a market capitalization of $168.64M with a P/E ratio of -3.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -158.8%.
Valuation Metrics
Market Cap
$168.64M
Enterprise Value
$107.73M
P/E Ratio
-3.9x
PEG Ratio
-8.8x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+12.6%
Current Ratio
4.2x
Debt/Equity
0.7x
ROE
-158.8%
ROA
-77.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cardiol Therapeutics Inc. (CRDL) Business Model
About Cardiol Therapeutics Inc.
What They Do
Develops therapies for heart diseases using CBD.
Business Model
Cardiol Therapeutics focuses on researching and producing innovative anti-inflammatory and anti-fibrotic treatments for severe cardiovascular conditions. The company primarily generates revenue through the development of its therapies, which aim to address significant unmet medical needs in heart disease, potentially transforming treatment protocols in the pharmaceutical sector.
Additional Information
Headquartered in Oakville, Ontario, Cardiol Therapeutics is recognized for its commitment to scientific research and development in the biotechnology and healthcare industries, targeting conditions like acute myocarditis and chronic heart failure.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
18
CEO
Mr. David G. Elsley MBA
Country
Canada
IPO Year
2018
Website
www.cardiolrx.comCardiol Therapeutics Inc. (CRDL) Latest News & Analysis
Latest News
Quick Summary
Cardiol Therapeutics' CEO David Elsley will discuss the Phase III MAVERIC trial and other developments in a live interview on X today at 12:00 PM EDT. Recording available post-event.
Why It Matters
Cardiol Therapeutics' CEO interview highlights critical trial updates and future drug developments, influencing investor sentiment on the company's growth potential and market position in heart disease therapies.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
The Phase III MAVERIC trial for CardiolRx™ in recurrent pericarditis has exceeded 50% enrollment, with completion expected by Q2 2026. Positive Phase II ARCHER data was published, showing reduced left ventricular mass in acute myocarditis patients.
Why It Matters
The initiation of the Phase III MAVERIC trial and positive Phase II results for CardiolRx™ signal potential growth and market interest, impacting future revenue and stock performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 4, 2026, at 10:30 a.m.
Why It Matters
Cardiol's participation in a major health conference highlights its commitment to progressing therapies, potentially boosting investor confidence and influencing stock performance.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Cardiol Therapeutics (NASDAQ: CRDL) announced Phase II ARCHER study results for CardiolRx™, showing effectiveness in treating acute myocarditis in 109 patients, published in ESC Heart Failure.
Why It Matters
Publication of Phase II ARCHER study results enhances credibility and could accelerate Cardiol's drug approval, impacting stock value and investor confidence in the company’s future prospects.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Cardiol Therapeutics Inc. has completed a private placement of units, including an over-allotment option, with Canaccord Genuity as the sole underwriter.
Why It Matters
Cardiol Therapeutics' successful private placement indicates strong investor confidence and provides capital for advancing its therapies, potentially enhancing its market position and stock value.
Source: Newsfile Corp
Market Sentiment:
Neutral
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
3 months ago
Quick Summary
Cardiol Therapeutics Inc. plans a private placement offering of 10,384,616 units at $1.30 each, aiming for $13.5 million in gross proceeds. An option for an additional 10% is also available.
Why It Matters
Cardiol Therapeutics secures $13.5 million in funding through a private placement, enhancing its cash position for developing heart disease therapies, potentially boosting investor confidence and share value.
Source: Newsfile Corp
Market Sentiment:
Neutral
Frequently Asked Questions About CRDL Stock
What is Cardiol Therapeutics Inc.'s (CRDL) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Cardiol Therapeutics Inc. (CRDL) has a median price target of $7.82. The highest price target is $9.15 and the lowest is $4.97.
Is CRDL stock a good investment in 2026?
According to current analyst ratings, CRDL has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRDL stock?
Wall Street analysts predict CRDL stock could reach $7.82 in the next 12 months. This represents a 417.9% increase from the current price of $1.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cardiol Therapeutics Inc.'s business model?
Cardiol Therapeutics focuses on researching and producing innovative anti-inflammatory and anti-fibrotic treatments for severe cardiovascular conditions. The company primarily generates revenue through the development of its therapies, which aim to address significant unmet medical needs in heart disease, potentially transforming treatment protocols in the pharmaceutical sector.
What is the highest forecasted price for CRDL Cardiol Therapeutics Inc.?
The highest price target for CRDL is $9.15 from at , which represents a 505.7% increase from the current price of $1.51.
What is the lowest forecasted price for CRDL Cardiol Therapeutics Inc.?
The lowest price target for CRDL is $4.97 from at , which represents a 229.4% increase from the current price of $1.51.
What is the overall CRDL consensus from analysts for Cardiol Therapeutics Inc.?
The overall analyst consensus for CRDL is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.82.
How accurate are CRDL stock price projections?
Stock price projections, including those for Cardiol Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 2:31 AM UTC